Prostacyclin Regulation of Allergic Inflammation

• Published in: Biomedicines Vol. 10; no. 11; p. 2862
• Main Authors: Patel, Kunj, Peebles, R. Stokes
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.11.2022; MDPI
• Subjects: Acids; airway remodeling; Allergens; allergic inflammation; Allergies; Animal models; anti-inflammatory; Asthma; CD4 antigen; Chemokines; Cytokines; Dendritic cells; Dosage and administration; Helper cells; Hypersensitivity; Inflammation; Kinases; Lavage; Lymphocytes; Lymphocytes T; Metabolism; Pathogenesis; proinflammatory; Prostacyclin; Prostaglandin endoperoxide synthase; Respiratory tract diseases; Review; Rodents; T cell receptors; Therapeutic targets; United States; anti-inflammatory; allergic inflammation; cytokines; prostacyclin; proinflammatory; airway remodeling
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10112862

Prostacyclin is a metabolic product of the cyclooxygenase pathway that is constitutively expressed and can be induced during inflammatory conditions. While prostacyclin and its analogs have historically been considered effective vasodilators and used in treating pulmonary hypertension, prostacyclin has demonstrated potent anti-inflammatory effects in animal models of allergic airway inflammation. In vitro studies reveal that prostacyclin directly inhibits type 2 cytokine production from CD4+ Th2 cells and ILC2 and reduces the ability of dendritic cells to generate Th2 cytokine production from CD4+ T cells in an antigen-specific manner. Thus, there is strong evidence that prostacyclin may be an additional therapeutic target for treating allergic inflammation and asthma in human subjects.